



Dr. Martin Fehr

Oberarzt mbF

Medizinische Onkologie und Hämatologie · Dept. I

Kontakt

Dr. Martin Fehr
Kantonsspital St Gallen, Rorschacherstrasse 95
9007 St. Gallen
Switzerland

T ++41 71 494 11 11
Martin.Fehr@kssg.ch

Homepage

www.kssg.ch/onkologie

Bereiche

Medizinische Onkologie und Hämatologie

Position

Oberarzt mbF

Forschungsgebiet

Lymphome
Hämatologische Erkrankungen

Mitgliedschaften

FMH, ESMO

Publikationen (15)

Brune M, Cogliatti S, Ossenkuppele G, Löwenberg B, Rudolf C, Li Q, Passweg J, Mazzuchelli L, Medinger M, Tzankov A, Fehr M, Grobholz R, Stussi G, Lundberg P, Vela V, Heim D, Manz M, Haralambieva E, Pabst T, Banz Y, Bargetzi M, Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK). Effects of lenalidomide on the bone marrow microenvironment in acute myeloid leukemia: Translational analysis of the HOVON103 AML/SAKK30/10 Swiss trial cohort. *Ann Hematol* 2021; 100:1169-1179.

Moccia A, Mingrone W, Novak U, Pflieger C, Richter P, Rütli M, Schmidt A, Stenner F, Voegeli M, Zander T, Zucca E, Mey U, Lang N, Aeppli S, Güsewell S, Bargetzi M, Caspar C, Brülisauer D, Ebnöther M, Fehr M, Fischer N, Ghilardi G, Krasniqi F, Hitz F. Clinical characteristics and outcome of patients over 60 years with Hodgkin lymphoma treated in Switzerland. *Hematol Oncol* 2020; 39:196-204.

Araf S, Fitzgibbon J, Okosun J, Johnson P, Davies A, Rimsza L, Scott D, Graham T, Barrington S, Forrer F, Kumar E, Cogliatti S, Wang J, Bewicke-Copley F, Korfi K, Fehr M. Genetic heterogeneity highlighted by differential FDG-PET response in diffuse large B-cell lymphoma. *Haematologica* 2020; 105:318-321.

Pirker I, Rubbert-Roth A, von Kempis J, Fehr M, Neumann T. Tocilizumab in a patient with newly diagnosed rheumatoid arthritis secondary to checkpoint inhibitor therapy. *Clin Exp Rheumatol* 2020

Fehr M, Cathomas G, Graber A, Markert E, Gaus E, Boggian K. Multi-fungal sepsis and mucormycosis of the central nervous system in a patient treated with ibrutinib, a case report and review of the literature. *Med Mycol Case Rep* 2019; 27:14-16.

Fehr M, Maranta A, Reichegger H, Gillessen Sommer S, Cathomas R. Carboplatin dose based on actual renal function: no excess of acute haematotoxicity in adjuvant treatment in seminoma stage I. *ESMO Open* 2018; 3:e000320.

Fehr M, Müller J, Knitel M, Fornaro J, Horber D, Koeberle D, Cerny T, Gueller U. Early Postoperative FDG-PET-CT Imaging Results in a Relevant Upstaging in the pN2 Subgroup of Stage III Colorectal Cancer Patients. *Clin Colorectal Cancer* 2017

Feller A, Clough-Gorr K, Arndt V, Steiner A, Mousavi M, Frick H, Bouchardy C, Bordoni A, Fehr M, The Nicer Working Group. Trends in incidence of oesophageal and gastric cancer according to morphology and anatomical location, in Switzerland 1982-2011. *Swiss Med Wkly* 2015; 145:w14245.

Zeuge U, Fehr M, Meyenberger C, Sulz M. Mind the sump! - diagnostic challenge of a rare complication of choledochoduodenostomy. *Case Rep Gastroenterol* 2014; 8:358-63.

Zeuge U, Fehr M, Meyenberger C, Sulz M. Mind the Sump! - Diagnostic Challenge of a Rare Complication of Choledochoduodenostomy. *Case Reports in Gastroenterology* 2014; 8:358-363.

Fehr M, Geldart T, Klingbiel D, Cathomas R. Measurement or estimation of glomerular filtration rate in seminoma patients: Quite another cup of tea. *Eur J Cancer* 2014; 50:2176-7.

Cathomas R, von Moos R, Nagaraj N, Simmonds P, Wheeler M, Ellis S, Mead G, Geldart T, Klingbiel D, Fehr M. Relevant risk of carboplatin underdosing in cancer patients with normal renal function using estimated GFR: lessons from a stage I seminoma cohort. *Ann Oncol* 2014; 25:1591-7.

Strebel R, Winterhalder R, Morant R, Pless M, Huber U, Fehr M, Gillessen Sommer S, Schmid H, Sulser T, Cathomas R. Multidisciplinary care in patients with prostate cancer: room for improvement. Support Care Cancer 2013; 21:2327-33.

Strebel R, Winterhalder R, Morant R, Pless M, U H, Fehr M, Gillessen S, Schmid H, Sulser T, Cathomas R. Multidisciplinary care in patients with prostate cancer: room for improvement. Support Care Cancer 2013; 21:2327-33.

Fehr M, Templeton A, Cogliatti S, Aebersold F, Egli F, Gillessen Sommer S, Cathomas R. Primary manifestation of small lymphocytic lymphoma in the prostate. Onkologie 2009; 32:586-8.

Projekte (8)

CAR T- Cell EBMT Registry data processing framework

Klinische Forschung - 30.07.2021 - 31.12.2026

Laufend

A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Re-lapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Klinische Forschung - 15.03.2021 - 07.04.2030

Geplant

EMCL-Registry of the European Mantle Cell Lymphoma study group

Klinische Forschung - 20.12.2019 - 20.12.2025

Geplant

SAKK 30/15; HOVON 135: A randomized phase II multicenter study to assess the tolerability and efficacy of the addition of ibrutinib to 10-day decitabine in UNFIT (i.e. HCT-CI ≥ 3) AML and high risk myelodysplasia (MDS) (IPSS-R > 4.5) patients aged ≥ 66 years. A study in the frame of the masterprotocol of parallel randomized phase II studies in UNFITolder AML/high-risk MDS patients

Klinische Forschung - 27.10.2016 - 31.07.2018

Automatisch geschlossen

Merck EORTC 1325 / MK-3475-054 - Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, double-blind Phase 3 trial of the EORTC Melanoma Group

Klinische Forschung - 01.03.2016 - 01.03.2020

Automatisch geschlossen

Rituximab with or without Ibrutinib for untreated patients with advanced follicular lymphoma in need of therapy. A randomized, double-blinded, SAKK and NLG collaborative Phase II trial

Klinische Forschung - 15.10.2015 - 31.12.2029

Laufend

Combination of ibrutinib and bortezomib followed by ibrutinib maintenance to treat patients with relapsed and refractory mantle cell lymphoma; a multicenter Phase I/II trial

Klinische Forschung - 09.09.2015 - 31.03.2021

Automatisch geschlossen

HOVON 103 / SAKK 30/10 protocol Tosedostat

Klinische Forschung - 19.03.2015 - 19.03.2015

Automatisch geschlossen

Kantonsspital St.Gallen
Rorschacher Strasse 95
CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch